Nilsen P A, Meling A B, Abildgaard U
Acta Obstet Gynecol Scand. 1976;55(1):39-44. doi: 10.3109/00016347609156781.
Inhibition of lactation was studied in 38 puerperal women in a double blind trial to assess the effect of bromocriptine in comparison with diethylstilboestrol (DS). Simultaneously the influence of both compounds on blood clotting was studied, along with a control group of 20 women not receiving any medication. Bromocriptine was given in a daily dose of 5 mg for 14 days and DS in a daily dose of 20 mg for 7 days followed by a placebo for a further 7 days. The first doses were not later than 8 hours after delivery. Both compounds showed an inhibitory effect on the onset of lactation and mammary congestion. This inhibitory effect on both parameters was significantly in favour of bromocriptine during the last days of the treatment due to rebound in the DS group. The bromocriptine doses used (5 mg daily for 2 weeks) caused no objective side effects and no subjective restraint. Treatment with bromocriptine caused no untoward effect on the blood clotting, while in the DS group a slower return to normal antithrombin III could be observed. Also in this group one case of thrombophlebitis occurred. Bromocriptine can be administered to puerperal women for the suppression of lactation.
在一项双盲试验中，对38名产后妇女进行了泌乳抑制研究，以评估溴隐亭与己烯雌酚（DS）相比的效果。同时，研究了这两种化合物对血液凝固的影响，并设置了一个由20名未接受任何药物治疗的妇女组成的对照组。溴隐亭每日剂量为5毫克，服用14天；DS每日剂量为20毫克，服用7天，之后再服用7天安慰剂。首剂给药不晚于分娩后8小时。两种化合物对泌乳开始和乳腺充血均有抑制作用。由于DS组出现反弹，在治疗的最后几天，溴隐亭对这两个参数的抑制作用明显更优。所用的溴隐亭剂量（每日5毫克，持续2周）未引起客观副作用和主观不适。溴隐亭治疗对血液凝固没有不良影响，而在DS组中，可观察到抗凝血酶III恢复正常的速度较慢。该组还发生了1例血栓性静脉炎。溴隐亭可用于产后妇女以抑制泌乳。
